No image available for this title

LITERATURE

Remdesivir for the Treatment of Covid-19 — Final Report


Our data show that remdesivir was superior to placebo in shortening the time to
recovery in adults who were hospitalized with Covid-19 and had evidence of lower
respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTT-1 ClinicalTrials.gov number, NCT04280705.)


Availability

Jubi-R-001Titan CenterAvailable

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
n engl j med 2020
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous